Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00674063 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess the Efficacy and Safety of Two Dosing Regimens of Alefacept in Subjects Weighing Between 100kg and 150kg With Moderate to Severe Chronic Plaque Psoriasis
A Phase 3 study of Chronic Plaque Psoriasis, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 78
- Enrollment target
- 17
- Study locations
NCT00674063: Completed Phase 3 study of Chronic Plaque Psoriasis, sponsored by Astellas Pharma.
NCT00674063 is a Phase 3 study of Chronic Plaque Psoriasis that has completed, run by Astellas Pharma. The registered enrollment target is 78 participants, below the 1,119-participant average among 6 other Chronic Plaque Psoriasis trials with a reported enrollment target (93% lower). The trial reports 17 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00674063, a Phase 3 study of Chronic Plaque Psoriasis, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 78 participants
- Enrollment target
- 17
- Study locations
Study Summary
Comparison of two dosing regimens of Alefacept in subjects weighing between 100kg and 150kg with moderate to severe Chronic Plaque Psoriasis
Conditions Studied
Interventions
- DRUG alefacept
Study Locations (17)
Ontario
- - Hamilton
- - London
- - Waterloo
- - Windsor
Oregon
- - Lake Oswego
- - Portland
Tennessee
- - Goodlettsville
- - Nashville
Arkansas
- - Hot Springs
Minnesota
- - Fridley
Nebraska
- - Omaha
New Jersey
- - East Windsor
New York
- - Stony Brook
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2003-07 |
| Est. Completion | 2004-04 |
| Phase | Phase 3 |
What the finished NCT00674063 record still lists
NCT00674063 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 78 participants, a relatively small participant target, below the 1,119-participant average among 6 other Chronic Plaque Psoriasis trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Chronic Plaque Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which alefacept is the first listed.
NCT00674063 lists 17 locations in 12 states (Ontario, Oregon, Tennessee).
Frequently Asked Questions
What is clinical trial NCT00674063 about?
NCT00674063 is a clinical study titled "A Study to Assess the Efficacy and Safety of Two Dosing Regimens of Alefacept in Subjects Weighing Between 100kg and 150kg With Moderate to Severe Chronic Plaque Psoriasis". Comparison of two dosing regimens of Alefacept in subjects weighing between 100kg and 150kg with moderate to severe Chronic Plaque Psoriasis
What is the current status of trial NCT00674063?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 78 participants. The study started on 2003-07. Estimated completion is 2004-04.
What conditions does trial NCT00674063 study?
This clinical trial studies the following conditions: Chronic Plaque Psoriasis.
What interventions are being tested in trial NCT00674063?
The interventions under investigation include: alefacept (DRUG).
Who is sponsoring clinical trial NCT00674063?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00674063 being conducted?
This trial has 17 study locations across Arkansas, Minnesota, Nebraska, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Plaque Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate Safety and Efficacy of Different Doses of Bimekizumab in Patients With Chronic Plaque Psoriasis
COMPLETED · Phase 2
-
Study to Evaluate the Immune Response to Pneumococcal Vaccine in Alefacept-treated Adults With Chronic Plaque Psoriasis
COMPLETED · Phase 4
-
Chronic Plaque Psoriasis (Ps) Registry
COMPLETED
-
Study to Evaluate the Effect of Secukinumab Compared to Placebo on Aortic Vascular Inflammation in Subjects With Moderate to Severe Plaque Psoriasis
COMPLETED · Phase 4
-
A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Bimekizumab in Patients With Chronic Plaque Psoriasis
COMPLETED · Phase 2
-
A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02397668 · 78 participants · NA
CorMatrix Cor TRICUSPID ECM Valve Replacement Study
- NCT03321656 · 78 participants · Phase 2
Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
- NCT03687814 · 78 participants · NA
Low FODMAP Plus PEG 3350 for the Treatment of Patients with Irritable Bowel Syndrome-Constipation
- NCT04018872 · 78 participants · Phase 2
Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia